Literature DB >> 31373227

Utility of Self-Destructing CRISPR/Cas Constructs for Targeted Gene Editing in the Retina.

Fan Li1,2,3, Sandy S C Hung2, Mohd Khairul Nizam Mohd Khalid1, Jiang-Hui Wang2,4, Vicki Chrysostomou2,4, Vickie H Y Wong5, Vikrant Singh1, Kristof Wing1, Leilei Tu6, James A Bender7, Alice Pébay2,4,8, Anna E King7, Anthony L Cook7, Raymond C B Wong2,4, Bang V Bui5, Alex W Hewitt1,2,4, Guei-Sheung Liu1,2,4,6.   

Abstract

Safe delivery of CRISPR/Cas endonucleases remains one of the major barriers to the widespread application of in vivo genome editing. We previously reported the utility of adeno-associated virus (AAV)-mediated CRISPR/Cas genome editing in the retina; however, with this type of viral delivery system, active endonucleases will remain in the retina for an extended period, making genotoxicity a significant consideration in clinical applications. To address this issue, we have designed a self-destructing "kamikaze" CRISPR/Cas system that disrupts the Cas enzyme itself following expression. Four guide RNAs (sgRNAs) were initially designed to target Streptococcus pyogenes Cas9 (SpCas9) and after in situ validation, the selected sgRNAs were cloned into a dual AAV vector. One construct was used to deliver SpCas9 and the other delivered sgRNAs directed against SpCas9 and the target locus (yellow fluorescent protein [YFP]), in the presence of mCherry. Both constructs were packaged into AAV2 vectors and intravitreally administered in C57BL/6 and Thy1-YFP transgenic mice. After 8 weeks, the expression of SpCas9 and the efficacy of YFP gene disruption were quantified. A reduction of SpCas9 mRNA was found in retinas treated with AAV2-mediated YFP/SpCas9 targeting CRISPR/Cas compared with those treated with YFP targeting CRISPR/Cas alone. We also show that AAV2-mediated delivery of YFP/SpCas9 targeting CRISPR/Cas significantly reduced the number of YFP fluorescent cells among mCherry-expressing cells (∼85.5% reduction compared with LacZ/SpCas9 targeting CRISPR/Cas) in the transfected retina of Thy1-YFP transgenic mice. In conclusion, our data suggest that a self-destructive "kamikaze" CRISPR/Cas system can be used as a robust tool for genome editing in the retina, without compromising on-target efficiency.

Entities:  

Keywords:  CRISPR/Cas9; in vivo genome editing; retina

Mesh:

Substances:

Year:  2019        PMID: 31373227     DOI: 10.1089/hum.2019.021

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  12 in total

Review 1.  The application and progression of CRISPR/Cas9 technology in ophthalmological diseases.

Authors:  Xumeng Hu; Beibei Zhang; Xiaoli Li; Miao Li; Yange Wang; Handong Dan; Jiamu Zhou; Yuanmeng Wei; Keke Ge; Pan Li; Zongming Song
Journal:  Eye (Lond)       Date:  2022-08-01       Impact factor: 4.456

Review 2.  Therapeutic in vivo delivery of gene editing agents.

Authors:  Aditya Raguram; Samagya Banskota; David R Liu
Journal:  Cell       Date:  2022-07-06       Impact factor: 66.850

Review 3.  New Editing Tools for Gene Therapy in Inherited Retinal Dystrophies.

Authors:  Juliette Pulman; José-Alain Sahel; Deniz Dalkara
Journal:  CRISPR J       Date:  2022-05-03

Review 4.  CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors.

Authors:  Dan Wang; Feng Zhang; Guangping Gao
Journal:  Cell       Date:  2020-04-02       Impact factor: 41.582

5.  Increasing the Specificity of AAV-Based Gene Editing through Self-Targeting and Short-Promoter Strategies.

Authors:  Camilo Breton; Thomas Furmanak; Alexa N Avitto; Melanie K Smith; Caitlin Latshaw; Hanying Yan; Jenny A Greig; James M Wilson
Journal:  Mol Ther       Date:  2020-12-25       Impact factor: 11.454

6.  AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9.

Authors:  Ang Li; Mark R Tanner; Ciaran M Lee; Ayrea E Hurley; Marco De Giorgi; Kelsey E Jarrett; Timothy H Davis; Alexandria M Doerfler; Gang Bao; Christine Beeton; William R Lagor
Journal:  Mol Ther       Date:  2020-04-19       Impact factor: 11.454

Review 7.  Molecular Therapies for Inherited Retinal Diseases-Current Standing, Opportunities and Challenges.

Authors:  Irene Vázquez-Domínguez; Alejandro Garanto; Rob W J Collin
Journal:  Genes (Basel)       Date:  2019-08-28       Impact factor: 4.096

Review 8.  Application of CRISPR Tools for Variant Interpretation and Disease Modeling in Inherited Retinal Dystrophies.

Authors:  Carla Fuster-García; Belén García-Bohórquez; Ana Rodríguez-Muñoz; José M Millán; Gema García-García
Journal:  Genes (Basel)       Date:  2020-04-27       Impact factor: 4.096

Review 9.  CRISPR FokI Dead Cas9 System: Principles and Applications in Genome Engineering.

Authors:  Maryam Saifaldeen; Dana E Al-Ansari; Dindial Ramotar; Mustapha Aouida
Journal:  Cells       Date:  2020-11-21       Impact factor: 6.600

Review 10.  Genome-Editing Strategies for Treating Human Retinal Degenerations.

Authors:  Joel Quinn; Ayesha Musa; Ariel Kantor; Michelle E McClements; Jasmina Cehajic-Kapetanovic; Robert E MacLaren; Kanmin Xue
Journal:  Hum Gene Ther       Date:  2020-11-19       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.